Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant
Clinical Advances in Hematology and Oncology H&o 12(8 Suppl. 16): 20
2014
ISSN/ISBN: 1543-0790 PMID: 25768999 Document Number: 678696
Document emailed within 1 workday
Related Documents
O'Sullivan, C.C.; Ozdemirli, M.; Bazylewicz, M.; Cheson, B.D. 2013: Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma Clinical Advances in Hematology and Oncology: H&o 11(6): 382-385Mengarelli, A.; Iori, A.Paola.; Cerretti, R.; Cerilli, L.; Romano, A.; Arcese, W. 2002: Increasing risk of relapse after allogeneic stem cell transplant for adult acute lymphoblastic leukemia in > or = 2nd complete remission induced by highly intensive chemotherapy Haematologica 87(7): 782-784
Satwani, P. 2007: Reduced-intensity conditioning allogeneic stem cell transplantation in pediatric patients Clinical Advances in Hematology and Oncology: H&o 5(5): 357-359
Al-Mansour, M.; Al-Maghraby, H.; Shirah, B. 2020: Transformation of Grade i Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD30+ ALK1- with Complete Response to Brentuximab Vedotin and High-Dose Methotrexate Gulf Journal of Oncology 1(33): 87-90
Christiansen, N.P.; Haake, R.J.; Hurd, D.D. 1991: Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant Bone Marrow Transplantation 7(6): 435-437
Cao, Z.G.; Wang, Z.H.; Sun, J.Z.; Liu, M.; Zhou, X.Y.; Yang, Q.M. 2016: A case report of refractory ALK-positive anaplastic large cell lymphoma treated with Brentuximab vedotin Zhonghua Zhong Liu Za Zhi 38(9): 715-716
Bearman, S.I. 2003: Reduced-intensity allogeneic stem cell transplantation Current Hematology Reports 2(4): 277-286
Cooper, M.H.; Maraninchi, D.; Gastaut, J.A.; Mannoni, P.; Carcassonne, Y. 1993: HIV infection in autologous and allogeneic bone marrow transplant patients: a retrospective analysis of the Marseille bone marrow transplant population Journal of Acquired Immune Deficiency Syndromes 6(3): 277-284
Hołowiecki, J.; Giebel, S.; Walewski, J.; Krawczyk-Kuliś, M.łg.; Hellmann, A.; Skotnicki, A.; Dmoszyńska, A.; Romejko, J.; Czyz, J.ła.; Jurczak, W.; Kachel, Łu.; Wojnar, J.; Stella-Hołowiecka, B.; Saduś-Wojciechowska, M.; Sułek, K.; Jedrzejczak, W.ła.; Robak, T.; Mariańska, B.; Szczylik, C.; Warzocha, K. 2003: Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. the experience of Polish lymphoma research group Polskie Archiwum Medycyny Wewnetrznej 110(2): 863-868
Nakai, K.; Mineishi, S.; Kami, M.; Kanda, Y.; Tanosaki, R.; Takaue, Y. 2003: The feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation from a related donor with HLA one-antigen with or without one-allele mismatch Haematologica 88(1): 115-117
Cheson, B.D.; Phillips, P.H. 1997: Clinical trials referral resource. new autologous stem-cell transplant protocols Oncology 11(2): 178-180
Stamatović, D.; Balint, B.; Tukić, L.; Elez, M.; Tarabar, O.; Todorović, M.; Todorić-Zivanović, B.; Ostojić, G.; Tatomirović, Z.; Marjanović, S.; Malesević, M. 2012: Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy Vojnosanitetski Pregled 69(1): 37-42
Nethers, K.; Messina, J.; Seminario-Vidal, L. 2017: Eccrine squamous syringometaplasia in an allogenic stem cell transplant patient undergoing chemotherapy Dermatology Online Journal 23(9)
Leong, S.S.; Teo, C.P.; Tao, M.; Ang, P.T. 1998: Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours Singapore Medical Journal 39(9): 396-398
Esteban, J.M.; Somlo, G. 1995: Skin biopsy in allogeneic and autologous bone marrow transplant patients: a histologic and immunohistochemical study and review of the literature Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 8(1): 59-64
Fujii, N.; Maeda, Y.; Takenaka, K.; Shinagawa, K.; Imai, T.; Kozuka, T.; Ikeda, K.; Sunami, K.; Hiramatsu, Y.; Ishimaru, F.; Niiya, K.; Harada, M. 2000: Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen with cytarabine and cyclophosphamide: report of 2 cases International Journal of Hematology 72(4): 499-503
Mukaiyama, T.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Aiba, K.; Matsuoka, A.; Matsumura, T.; Ogihara, A.; Sumida, T. 1992: High-dose thio-TEPA with escalating doses of epirubicin and autologous hematopoietic stem cell transplant for refractory cancers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(2): 189-194
Voorhees, P.M.; Usmani, S.Z. 2016: The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy Clinical Advances in Hematology and Oncology: H&o 14(9): 719-728
Yu, Z.-p.; Ding, J.-h.; Chen, B.-a.; Wu, F.; Gao, C.; Sun, Y.-y.; Chen, J.; Zhao, G.; Wang, J.; Li, Y.-f.; Ding, B.-h.; Qian, J. 2011: Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation Zhonghua Zhong Liu Za Zhi 33(4): 283-286
Sundin, M.; Le Blanc, K.; Ringdén, O.; Barkholt, L.; Omazic, B.; Lergin, C.; Levitsky, V.; Remberger, M. 2006: The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation Haematologica 91(8): 1059-1067